HRP20221018T1 - Liječenje katapleksije - Google Patents

Liječenje katapleksije Download PDF

Info

Publication number
HRP20221018T1
HRP20221018T1 HRP20221018TT HRP20221018T HRP20221018T1 HR P20221018 T1 HRP20221018 T1 HR P20221018T1 HR P20221018T T HRP20221018T T HR P20221018TT HR P20221018 T HRP20221018 T HR P20221018T HR P20221018 T1 HRP20221018 T1 HR P20221018T1
Authority
HR
Croatia
Prior art keywords
compound
formula
use according
enantiomer
carbon atoms
Prior art date
Application number
HRP20221018TT
Other languages
English (en)
Croatian (hr)
Inventor
Moise A. Khayrallah
Gary Bream
Stephen E. Butts
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Limited, Sk Biopharmaceuticals Co., Ltd. filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of HRP20221018T1 publication Critical patent/HRP20221018T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02Carbamic acids; Salts of carbamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20221018TT 2013-03-13 2014-03-12 Liječenje katapleksije HRP20221018T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
EP14778088.6A EP2968208B1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Publications (1)

Publication Number Publication Date
HRP20221018T1 true HRP20221018T1 (hr) 2023-01-06

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221018TT HRP20221018T1 (hr) 2013-03-13 2014-03-12 Liječenje katapleksije

Country Status (21)

Country Link
US (7) US9359290B2 (enExample)
EP (1) EP2968208B1 (enExample)
JP (2) JP6530741B2 (enExample)
KR (1) KR102192554B1 (enExample)
CN (1) CN105431142B (enExample)
AU (1) AU2014248849B2 (enExample)
BR (1) BR112015022197B1 (enExample)
CA (1) CA2905457A1 (enExample)
DK (1) DK2968208T3 (enExample)
ES (1) ES2927675T3 (enExample)
HR (1) HRP20221018T1 (enExample)
HU (1) HUE060060T2 (enExample)
MX (1) MX381381B (enExample)
MY (1) MY177740A (enExample)
PH (1) PH12015502075B1 (enExample)
PT (1) PT2968208T (enExample)
RU (2) RU2019114940A (enExample)
SG (1) SG11201507121RA (enExample)
SI (1) SI2968208T1 (enExample)
TW (2) TWI663971B (enExample)
WO (1) WO2014164969A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217949B (zh) * 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
CA2765463C (en) 2009-06-22 2018-10-09 Moise A. Khayrallah Methods for treating or preventing fatigue
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
TW201919605A (zh) 2013-07-18 2019-06-01 南韓商愛思開生物製藥股份有限公司 肥胖之治療
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102513800B1 (ko) 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
EP3630072A4 (en) * 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
WO2019027941A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals International Iii Limited CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF
CA3075478A1 (en) * 2017-09-12 2019-03-21 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) * 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
IL282311B2 (en) * 2018-10-15 2025-08-01 Axsome Therapeutics Inc Use of reboxetine to treat narcolepsy
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
PE20230181A1 (es) * 2019-12-03 2023-02-01 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
CZ285829B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2561945A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ghb 조성물
CN101132787A (zh) 2004-10-28 2008-02-27 Sk株式会社 抑郁的辅助疗法
CN101217949B (zh) * 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
JP5094720B2 (ja) 2005-07-26 2012-12-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ サブスタンス関連障害を処置する方法
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
US8283127B2 (en) * 2006-11-10 2012-10-09 Dimerix Bioscience Pty Ltd. Detection system and uses therefor
CA2765463C (en) * 2009-06-22 2018-10-09 Moise A. Khayrallah Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
RU2556585C2 (ru) 2009-11-06 2015-07-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома дефицита внимания и гиперактивности
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi

Also Published As

Publication number Publication date
SG11201507121RA (en) 2015-10-29
EP2968208A1 (en) 2016-01-20
US20230416195A1 (en) 2023-12-28
SI2968208T1 (sl) 2023-02-28
US11713292B2 (en) 2023-08-01
US11072579B2 (en) 2021-07-27
PH12015502075A1 (en) 2016-01-18
US20250059135A1 (en) 2025-02-20
US10259780B2 (en) 2019-04-16
US20140275244A1 (en) 2014-09-18
WO2014164969A1 (en) 2014-10-09
US20190218174A1 (en) 2019-07-18
RU2019114940A (ru) 2019-06-28
TWI684450B (zh) 2020-02-11
US9585863B2 (en) 2017-03-07
ES2927675T3 (es) 2022-11-10
HUE060060T2 (hu) 2023-01-28
MX2015012644A (es) 2016-06-21
EP2968208B1 (en) 2022-07-20
US20170137375A1 (en) 2017-05-18
JP6530741B2 (ja) 2019-06-12
US9359290B2 (en) 2016-06-07
US20220017457A1 (en) 2022-01-20
TW201919606A (zh) 2019-06-01
MY177740A (en) 2020-09-23
PT2968208T (pt) 2022-10-28
MX381381B (es) 2025-03-12
KR102192554B1 (ko) 2020-12-18
DK2968208T3 (da) 2022-08-22
EP2968208A4 (en) 2016-10-12
TW201513856A (zh) 2015-04-16
US20160250176A1 (en) 2016-09-01
AU2014248849B2 (en) 2018-08-30
PH12015502075B1 (en) 2016-01-18
CA2905457A1 (en) 2014-10-09
KR20150139522A (ko) 2015-12-11
BR112015022197A2 (pt) 2017-07-18
JP2016512531A (ja) 2016-04-28
JP2019147830A (ja) 2019-09-05
RU2019114940A3 (enExample) 2019-12-25
CN105431142B (zh) 2019-04-26
HK1219236A1 (zh) 2017-03-31
US12162821B2 (en) 2024-12-10
BR112015022197B1 (pt) 2022-06-07
TWI663971B (zh) 2019-07-01
RU2015143610A3 (enExample) 2018-03-21
RU2015143610A (ru) 2017-04-20
CN105431142A (zh) 2016-03-23
AU2014248849A1 (en) 2015-10-08
RU2689984C2 (ru) 2019-05-30
BR112015022197A8 (pt) 2019-11-26

Similar Documents

Publication Publication Date Title
HRP20221018T1 (hr) Liječenje katapleksije
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
BR112014025564A2 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
ME02490B (me) Hemijska jedinjenja
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
HRP20211392T1 (hr) INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX2015010971A (es) Derivado novedoso de pirazol.
NZ716840A (en) Combination formulation of two antiviral compounds
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
BR112013017302A2 (pt) formulações de imunossupressor
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MX2009007914A (es) Composiciones farmaceuticas novedosas.
PH12015502429A1 (en) Dicarboxylic acid compound
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma